Physician profile
Nirmanmoh Bhatia
NPI 1720374911
$11,633.08
in general payments reported to CMS, 2019-2025
24 companies · $1,831 in 2025
The $1,831 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,566 · 2020: $1,157 · 2021: $785 · 2022: $2,873 · 2023: $224 · 2024: $198 · 2025: $1,831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,138 · Food and Beverage: $1,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,138.44 |
| Food and Beverage | $1,113.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,181.99 | 2019-2025 | Triclip, Mitraclip |
| Penumbra, INC. | $2,158.32 | 2022 | |
| Edwards Lifesciences Corporation | $1,721.41 | 2019-2021 | |
| Medtronic Vascular, INC. | $1,046.04 | 2019-2020 | |
| Boston Scientific Corporation | $690.44 | 2019-2024 | Watchman Access System, Infinion 16 |
| Novartis Pharmaceuticals Corporation | $215.59 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $200.34 | 2022-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $167.47 | 2021-2022 | |
| Chiesi USA, INC. | $161.98 | 2020-2024 | Kengreal |
| Cardiovascular Systems INC. | $132.75 | 2019 | |
| Merck Sharp & Dohme LLC | $127.68 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $124.95 | 2025 | Sylvant |
| Rigel Pharmaceuticals, INC. | $124.85 | 2021 | |
| Inari Medical, INC. | $121.91 | 2019 | |
| Genzyme Corporation | $117.16 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $115.51 | 2022 | |
| Pfizer INC. | $65.15 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.00 | 2025 | |
| Amgen INC. | $27.68 | 2020-2021 | |
| Angiodynamics, INC. | $27.56 | 2019 | |
| Acutus Medical, INC. | $21.87 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $19.25 | 2023 | Camzyos |
| Novo Nordisk INC | $15.26 | 2022 | |
| Braintree Laboratories, INC. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirmanmoh Bhatia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.